NASDAQ:PTLA

Portola Pharmaceuticals (PTLA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $18.03
▼
$18.03
50-Day Range: $18.03
▼
$18.03
52-Week Range: $5.31
▼
$31.73

Volume: N/A
Average Volume: 3.17 million shs
Market Capitalization: $1.42 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Financials Insider Trades Institutional Ownership Headlines Options Chain SEC Filings Short Interest Social Media

About Portola Pharmaceuticals (NASDAQ:PTLA) Stock

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PTLA Stock News Headlines

April 15, 2023 | usnews.com

Portola Middle

March 25, 2023 | sfgate.com

Fault lines in Portola Valley

June 1, 2023 | Edge On The Street (Ad)

ChatGPT Is Already "Old School"

As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.

March 23, 2023 | usnews.com

Portola-Butler Continuation High School

February 18, 2023 | yahoo.com

Portola, United States - Weather Forecasts | Maps | News - Yahoo Weather

December 31, 2022 | forbes.com

Eagle Pharmaceuticals

November 21, 2022 | markets.businessinsider.com

Berman Tabacco Announces Class Action Settlement In Securities Litigation Involving Purchasers of Portola Pharmaceuticals, Inc. Common Stock

October 7, 2022 | investing.com

PTLA_old Historical Data

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

September 29, 2022 | seekingalpha.com

KPRX Kiora Pharmaceuticals, Inc.

October 19, 2020 | reuters.com

ALXN.O - Alexion Pharmaceuticals, Inc. Profile | Reuters

August 19, 2020 | bloomberg.com

PTLA LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation into Portola Pharmaceuticals, Inc., and Encour

August 6, 2020 | ca.finance.yahoo.com

Portola Pharmaceuticals, Inc. (PTLA)

July 24, 2020 | sg.finance.yahoo.com

Why Portola Pharmaceuticals Skyrocketed 25.6% Today

July 2, 2020 | seekingalpha.com

Alexion completes acquisition of Portola Pharma; SEC charges with FCPA violations

June 24, 2020 | finance.yahoo.com

Portola Pharmaceuticals Inc (PTLA): Hedge Funds Are Cashing Out

June 4, 2020 | finance.yahoo.com

KLXE, TORC, TERP, and PTLA SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

May 28, 2020 | www.nasdaq.com

Stock Alert: Alexion Pharma Up 7%

May 26, 2020 | finance.yahoo.com

MERGER ALERT - QES and PTLA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

May 22, 2020 | finance.yahoo.com

INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MINI, WLTW, PTLA

May 19, 2020 | finance.yahoo.com

KLXE, FSB, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

May 18, 2020 | finance.yahoo.com

Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

May 18, 2020 | finance.yahoo.com

MERGER ALERT - STML and PTLA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

May 15, 2020 | finance.yahoo.com

INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm

May 14, 2020 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, QES, and TERP Shareholders About Its Ongoing Investigations

May 14, 2020 | finance.yahoo.com

U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year

May 12, 2020 | seekingalpha.com

Portola Pharmaceuticals EPS misses by $0.07, misses on revenue

See More Headlines

PTLA Company Calendar

Last Earnings: 5/11/2020
Today: 6/01/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PTLA
CUSIP: N/A
CIK: 1269021
Web: www.portola.com
Phone: 650-246-7000
Fax: N/A
Employees: 324
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-290,660,000.00
Net Margins: -232.73%
Pretax Margin: N/A
Return on Equity: -267.86%
Return on Assets: -54.66%

Debt

Debt-to-Equity Ratio: 4.77
Current Ratio: 4.87
Quick Ratio: 4.82

Sales & Book Value

Annual Sales: $116.64 million
Price / Sales: 12.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.67 per share
Price / Book: 10.80

Miscellaneous

Outstanding Shares: 78,484,000
Free Float: N/A
Market Cap: $1.42 billion
Optionable: Optionable
Beta: 2.32

Key Executives

Ms. Mardi C. Dier (Age 55)
Exec. VP, Chief Bus. Officer & CFO

Dr. John T. Curnutte (Age 67)
Exec. VP and Head of R&D

Mr. J. Scott Garland M.B.A. (Age 50)
MBA, Pres & CEO

Cara Miller
VP of Investor Relations and Corp. Communications

Mr. John B. Moriarty Jr. (Age 51)
Exec. VP, Gen. Counsel & Sec.

Key Competitors

View All Competitors

PTLA Stock - Frequently Asked Questions

How were Portola Pharmaceuticals' earnings last quarter?: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.14. The biopharmaceutical company earned $26.40 million during the quarter, compared to the consensus estimate of $33.88 million. Portola Pharmaceuticals had a negative trailing twelve-month return on equity of 267.86% and a negative net margin of 232.73%. The business's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.02) earnings per share.
What other stocks do shareholders of Portola Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Amarin (AMRN), Exelixis (EXEL), NVIDIA (NVDA), Geron (GERN), ACADIA Pharmaceuticals (ACAD) and Aileron Therapeutics (ALRN).
What is Portola Pharmaceuticals' stock symbol?: Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

What is Portola Pharmaceuticals' stock price today?: One share of PTLA stock can currently be purchased for approximately $18.03.
How much money does Portola Pharmaceuticals make?: Portola Pharmaceuticals (NASDAQ:PTLA) has a market capitalization of $1.42 billion and generates $116.64 million in revenue each year. The biopharmaceutical company earns $-290,660,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis.
How many employees does Portola Pharmaceuticals have?: The company employs 324 workers across the globe.
How can I contact Portola Pharmaceuticals?: Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.portola.com. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at ir@portola.com.

This page (NASDAQ:PTLA) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Portola Pharmaceuticals (PTLA) Stock Forecast, Price & News

About Portola Pharmaceuticals (NASDAQ:PTLA) Stock

PTLA Stock News Headlines

PTLA Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PTLA Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info